Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Anne Deblander"'
Autor:
Josephine Van Cauwenberge, Karen Van Baelen, Marion Maetens, Tatjana Geukens, Ha Linh Nguyen, Ines Nevelsteen, Ann Smeets, Anne Deblander, Patrick Neven, Stijn Koolen, Hans Wildiers, Kevin Punie, Christine Desmedt
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-12 (2024)
Abstract Background The proportion of patients with breast cancer and obesity is increasing. While the therapeutic landscape of breast cancer has been expanding, we lack knowledge about the potential differential efficacy of most drugs according to t
Externí odkaz:
https://doaj.org/article/ac8267e2aba3472cb7db7eecd15b2673
Autor:
Hava Izci, Tim Tambuyzer, Jessica Vandeven, Jérôme Xicluna, Hans Wildiers, Kevin Punie, Nynke Willers, Eva Oldenburger, Els Van Nieuwenhuysen, Patrick Berteloot, Ann Smeets, Ines Nevelsteen, Anne Deblander, Harlinde De Schutter, Patrick Neven, Geert Silversmit, Freija Verdoodt
Publikováno v:
Archives of Public Health, Vol 79, Iss 1, Pp 1-8 (2021)
Abstract Background Registration and coding of cause of death is prone to error since determining the exact underlying condition leading directly to death is challenging. In this study, causes of death from the death certificates were compared to pat
Externí odkaz:
https://doaj.org/article/17c16a0f636a41db978cdf1fcc8912d0
Autor:
Josephine Van Cauwenberge, Kristien Borremans, Maxime Van Houdt, Anne Deblander, Patrick Berteloot, Sileny Han, Annouschka Laenen, Patrick Neven
Publikováno v:
JNCI: Journal of the National Cancer Institute.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bccdfcc4c02b9ad8a5cbdd6b1b71e247
https://doi.org/10.1093/jnci/djad089
https://doi.org/10.1093/jnci/djad089
Autor:
Charlotte Berteloot, Patrick Neven, Maja Vangoitsenhoven, Annouschka Laenen, Hans Wildiers, Kevin Punie, Ann Smeets, Ines Nevelsteen, Sileny Han, Thaïs Baert, Hilde Janssen, Eva Oldenburger, Adinda Baten, Patrick Berteloot, Rani Vanhoudt, Anne Deblander, Chantal Remmeriev, Christine Desmedt
Publikováno v:
Cancer Research. 83:P1-02
Background The Regan Composite Risk Score (RCRS) is a web-based prognostic and predictive calculator to guide the use of adjuvant exemestane plus ovarian function suppression (AI + OFS) versus tamoxifen plus ovarian function suppression (TAM + OFS) o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4df22799b8ccf40132db80a08c8d860b
https://doi.org/10.1158/1538-7445.sabcs22-p1-02-04
https://doi.org/10.1158/1538-7445.sabcs22-p1-02-04
Autor:
Anne Deblander, Ellen Reynders, Lise-Marie Kinnaer, Hans Wildiers, Christof Vulsteke, Hannelore Denys, W. Wynendaele, Philip R. Debruyne, Ximena Elzo-Kraemer, Isabelle Spoormans, Ahmad Awada, Carrie Visser, Veronique Cocquyt, Andrea Gombos, Patrick Neven, Patrick Berteloot, Veerle Foulon, Sandra De Coster, Kevin Punie, Marleen Borms, Eric Strobbe
Publikováno v:
Cancer Research. 81:PS9-06
BackgroundEverolimus in combination with exemestane is indicated for the treatment of hormone receptor-positive, HER 2-neg endocrine resistant advanced breast cancer in postmenopausal women. This study investigated treatment adherence, tolerability,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66273f2886fe969972e95731b4f4714a
https://doi.org/10.1158/1538-7445.sabcs20-ps9-06
https://doi.org/10.1158/1538-7445.sabcs20-ps9-06
Publikováno v:
Nursing Clinics of North America. 41:105-117
If well-designed, longitudinal observational studies (LOSs) can provide insights to the linkages between real-world outcomes and their multilevel determinants. In this article, some of the scientific and methodologic issues related to LOSs in pharmac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aca67269337cd3f9c1a7a750f4646d0d
https://doi.org/10.1016/j.cnur.2005.10.002
https://doi.org/10.1016/j.cnur.2005.10.002
Autor:
Tony Mets, Ivo Abraham, Anne Deblander, Jean Jacquy, Karen MacDonald, Maurits Vandewoude, Anne Sloesen
Publikováno v:
Current medical research and opinion
Despite response variability, cholinesterase inhibitors are recommended in mild to moderate Alzheimer's disease. Dose titration is common; however randomized controlled trials (RCTs) have mainly investigated fixed-dose regimens. We examined practice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1efcc5d0473b8026fbaecf5c38325df
https://pubmed.ncbi.nlm.nih.gov/17784995
https://pubmed.ncbi.nlm.nih.gov/17784995
Autor:
Tony Mets, Maurits Vandewoude, Jean Jacquy, Anne Deblander, Karen MacDonald, Anne Sloesen, Ivo Abraham
Publikováno v:
Current Medical Research & Opinion; Oct2007, Vol. 23 Issue 10, p2485-2501, 17p